Treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer showed positive 5-year overall survival (OS) outcomes that were consistent with the primary analysis of the phase 3 APACT clinical trial (NCT01964430) as well as a post hoc analysis.
During a presentation given during the ESMO World Congress on Gastrointestinal Cancer by Margaret A. Tempero of UCSF Helen Diller Family Comprehensive Cancer Center, it was suggested that although the study missed its primary end point of disease-free survival (DFS) improvement, the OS benefit observed signifies promise for the combination as treatment of resected pancreatic cancer. Read more . . .